All Articles

Review Article 
HER2-low breast cancer: insights on pathological testing
Yueping Liu
Translational Breast Cancer Research  
2023;
4:
15  
Review Article 
Breast biopsy techniques in a global setting—clinical practice review
Edibaldo Silva, Steven Meschter, Mona P. Tan
Translational Breast Cancer Research  
2023;
4:
14  
Review Article 
Key points of anti-tumor treatment in breast cancer patients with SARS-CoV-2 infection
Rui Ge
Translational Breast Cancer Research  
2023;
4:
13  
Review Article 
The association between perioperative opioids and breast cancer recurrence: a narrative review of the literature
Tanya E. Thomas, Kara Bowers, Daniel Gomez, Orly Morgan, Peter A. Borowsky, Rajib Dutta, Yaa Abu, Sabita Roy, Kristin E. Rojas
Translational Breast Cancer Research  
2023;
4:
12  
Original Article 
Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR+HER2 metastatic breast cancer
Yang Yuan, Shaohua Zhang, Tao Wang, Biyun Wang, Shusen Wang, Jing Shi, Tao Sun, Yongmei Yin, Quchang Ouyang, Jianbin Li, Yi Wen, Lijun Zhang, Zefei Jiang
Translational Breast Cancer Research  
2023;
4:
10  
Editorial Commentary 
Advances of HER2 testing for women with breast cancer
Mamatha Chivukula
Translational Breast Cancer Research  
2023;
4:
9  
Letter to the Editor 
Clinical considerations for estrogen receptor-negative/progesterone receptor-positive/HER2-negative (ERPR+HER2) breast cancer
Bruno Henrique Rala de Paula, Susanne Crocamo, Jose Bines
Translational Breast Cancer Research  
2023;
4:
8  
Review Article 
Breast cancer gene expression signatures: development and clinical significance—a narrative review
Siyan Li, Xinmiao Yu, Yingying Xu
Translational Breast Cancer Research  
2023;
4:
7  
Review Article 
Prospect of neoadjuvant/adjuvant immunotherapy in early-stage triple-negative breast cancer
Xiaopeng Hao, Xianqi Gao, Shanshan Yin, Zefei Jiang
Translational Breast Cancer Research  
2023;
4:
6  
Original Article 
A retrospective cohort study comparing reconstructive techniques and outcomes in post-mastectomy triple negative breast cancer patients
Adaah A. Sayyed, Parhom Towfighi, Romina Deldar, Nathan Aminpour, Olutayo Sogunro, Mansi Maini, Monika Masanam, Jennifer D. Son, Kenneth L. Fan, David H. Song
Translational Breast Cancer Research  
2023;
4:
5  
Original Article 
Molecular subtypes predict the prognosis of male breast cancer: a retrospective cohort study
Min Wang, Deyue Liu, Zhaoqi Zhang, Xueming Dai, Guiming Chen, Li Zhu
Translational Breast Cancer Research  
2023;
4:
4  
Original Article 
Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy
Xiaojia Wang, Wei Li, Yongmei Yin, Zhongsheng Tong, Qingyuan Zhang, Hong Zheng, Zhimin Shao, Huiping Li, Jin Yang, Jifeng Feng, Fan Wu, Francois Lamour, Eleonora Restuccia, Zefei Jiang
Translational Breast Cancer Research  
2023;
4:
3  
Clinical Practice Guideline 
Chinese Society of Breast Surgery (CSBrS) Practice Guideline 2022
Hongyu Xiang, Yinhua Liu; Chinese Society of Breast Surgery (CSBrS) of the Chinese Surgical Society of the Chinese Medical Association
Translational Breast Cancer Research  
2023;
4:
2  
Case Report 
Presentation of metastatic breast cancer as a large bowel obstruction in an elderly female with resultant diverting ileostomy: case report
Samantha Greenseid, Kelsey Staudinger, Rosemary Morgan, Kenneth Blake
Translational Breast Cancer Research  
2022;
3:
38  
Original Article: Case Series 
Risk-reducing surgery in PALB2 mutations carriers with breast cancer: a case series and literature review
Monika K. Masanam, Clark W. Pitcher, Olutayo Sogunro, Leah K. Starks, Allison B. Murray, Marc E. Boisvert
Translational Breast Cancer Research  
2022;
3:
37  
Editorial 
CSCO breast cancer management guidelines 2022: Australian perspective
Chen Han Yong, Anurag Gupta, Rohit Joshi
Translational Breast Cancer Research  
2022;
3:
36  
Editorial 
An engineering feat of small proportions
Gerald M. Higa
Translational Breast Cancer Research  
2022;
3:
35  
Editorial 
Differences between Japan and China in perioperative pharmacotherapy of early-stage breast cancer in breast cancer guidelines (2022 edition)
Takashi Yamanaka, Toshinari Yamashita
Translational Breast Cancer Research  
2022;
3:
34  
Review Article 
Strategies for the treatment of HER2+ advanced breast cancer based on clinical practice in Chinese patients: a roundtable discussion
Quchang Ouyang, Min Yan, Xiaojia Wang, Qingyuan Zhang
Translational Breast Cancer Research  
2022;
3:
33  
Review Article 
A round table discussion: clinical landscape of trastuzumab deruxtecan in breast cancer: a retrospective and prospective view
Xu Liang, Ying Yan, Guohong Song
Translational Breast Cancer Research  
2022;
3:
32  
Original Article 
Efficacy and safety of margetuximab plus chemotherapy vs. trastuzumab plus chemotherapy in Chinese patients with pretreated HER2-positive advanced metastatic breast cancer: results from a randomized, open-label, multicenter, phase II bridging study
Qingyuan Zhang, Quchang Ouyang, Wei Li, Joanne Chiu, Min Yan, Yen-Shen Lu, Sanyuan Sun, Huiping Li, Yingying Du, Xujuan Wang, Tao Sun, Yongmei Yin, Haibo Wang, Feng Ye, Kunwei Shen, Jingfen Wang, Yueyin Pan, Shusen Wang, Jin Yang, Xiaohong Wu, Ming-Shen Dai, Jing Cheng, Yuee Teng, Fang Su, Xinhong Wu, Jingdong He, Peifen Fu, Lulu Yang, Yuan Xin, Xiaojia Wang, Zefei Jiang
Translational Breast Cancer Research  
2022;
3:
31  
Consensus 
Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer (2023 edition)
Jianbin Li, Xiaojia Wang, Shusen Wang, Shu Wang, Tao Wang, Yueping Liu, Cuizhi Geng, Feng Jin, Yongmei Yin, Qingyuan Zhang, Erwei Song, Jiong Wu, Zefei Jiang; Chinese Society of Clinical Oncology Breast cancer committee; Chinese Anti-Cancer Association; Committee of Breast Cancer Society
Translational Breast Cancer Research  
2022;
3:
30